Scientist with needle

POPular Genetics

  • This randomized, prospective trial of 2,488 patients undergoing primary PCI with stent implantation assessed the use of a genotype-guided approach to oral P2Y12 inhibitor selection.
  • This study showed that a genotype-guided approach to therapy was noninferior to standard treatment with ticagrelor or prasugrel with respect to thrombotic events, and resulted in a lower incidence of bleeding.
  • Considering that ticagrelor/prasugrel cost 10-20X more than generic clopidogrel, CYP2C19 genotyping can significantly lower healthcare costs.
  • The POPular Genetics trial used Spartan’s RX CYP2C19 System.

Explore Related Resources

Which Test Are You Looking For?